Who
Troy Edward Wilson
Director
Company insider
Files Form 4 as: Director, Puma Biotechnology; President and CEO, Kura Oncology; Director, Atrium Therapeutics; Director, Avidity Biosciences; Director, Zosano Pharma.
In numbers
- Trades disclosed
- 177
- Buys
- 5
- Sells
- 24
- Bought
- $5.4M
- Sold
- $25.7M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 18 Oct 2013
- Last trade
- 14 Sep 2026
- Last filed
- 16 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Sep 2026filed 16 Sep 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Sold | $46K5,000 at $9.10 | filing |
| 14 Sep 2026filed 16 Sep 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Sold | $46K5,000 at $9.10 | filing |
| 24 Aug 2026filed 24 Aug 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Bought | $1.2M100,000 at $12.39 | filing |
| 24 Aug 2026filed 24 Aug 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Bought | $1.2M100,000 at $12.39 | filing |
| 17 Aug 2026filed 17 Aug 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Bought | $1.1M100,000 at $11.12 | filing |
| 17 Aug 2026filed 17 Aug 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Bought | $1.1M100,000 at $11.12 | filing |
| 12 Jun 2026filed 15 Jun 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Sold | $78K10,800 at $7.20 | filing |
| 12 Jun 2026filed 15 Jun 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Sold | $78K10,800 at $7.20 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code M | $38K6,103 at $6.15 | filing |
| 23 Mar 2026filed 25 Mar 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,103 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,103 at $0.00 | filing |
| 23 Mar 2026filed 25 Mar 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code M | $38K6,103 at $6.15 | filing |
| 27 Feb 2026filed 2 Mar 2026 | RNA Atrium Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 27 Feb 2026filed 2 Mar 2026 | RNA Atrium Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity BiosciencesBiotechnology | SEC FORM 4 Code D | —65,091 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity BiosciencesBiotechnology | SEC FORM 4 Code D | —13,711 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,034 | filing |
| 27 Feb 2026filed 27 Feb 2026 | Avidity Biosciencesoption or derivative | SEC FORM 4 Code D | —10,034 | filing |
News
Puma Biotechnology (NASDAQ:PBYI) Director Troy Edward Wilson Sells 5,000 Sharestickerreport.com · 17 Sep 2026Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in DiabetesKURA · manilatimes.net · 13 Oct 2026
1 headline in the last 90 days name Troy Edward Wilson; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.